BioSpace News Archive

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at ASN’s Kidney Week 2020 Reimagined from October 22-25, 2020.

The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, “Protein Degradation Drug Discovery”.

The Parkinson Foundation of the National Capital Area (PFNCA) will host its annual awareness and fundraising walk – Walk Off Parkinson’s – virtually on Oct. 14 and Oct. 20 , 2020. The program, which starts at 6:30 p.m. ET each day, features educational and inspirational content from 18 doctors who are Movement Disorder Specialists

careMESH today announced that Gustavo Bonany has been appointed as chief technology officer (CTO).

Proteor USA, LLC, a wholly owned subsidiary of the France based, Proteor Group, has signed an agreement with Ottobock to acquire a significant portion of the lower limb prosthetics portfolio of Freedom Innovations which demonstrates Proteor’s continued commitment and investment in the worldwide prosthetic industry.

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 161,000 shares of the company’s common stock, at a per share exercise price of $4.45, the closing trading price on October 7, and restricted stock units to acquire 80,500 shares of the company’s common stock.

National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the third quarter ended September 30, 2020.

- New data from the Phase 2 OASIS trial and its open-label extension for etrasimod in ulcerative colitis - Arena sponsored symposium: Opening the Door to Emerging Investigational Treatments in Ulcerative Colitis: What Awaits Us? [09-October-2020] SAN DIEGO , Oct. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new data from

Celerion , a leading clinical research organization (CRO) provider to the biopharmaceutical industry, will deliver a key address on the final day of the V

Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA). The committees met to discuss ALKS 3831 (olanzapine/samidorphan), an inves